Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review) - Wikidata - awgldk - TriplyDB

Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)

Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)

http://www.wikidata.org/entity/Q28081243

about

MicroRNA-211 promotes non-small-cell lung cancer proliferation and invasion by targeting MxA.Trial watch: DNA-based vaccines for oncological indications

P2860

Q47139048-DB6ADB49-B60D-4124-99A4-BBFF238BEF3E Q56893452-D60F9EDD-231E-4DF4-8A6A-271B502CF494

P2860

Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)

http://www.wikidata.org/entity/Q28081243

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Pemetrexed clinical studies in ...... mall cell lung cancer (Review)

@ast

Pemetrexed clinical studies in ...... mall cell lung cancer (Review)

@en

Pemetrexed clinical studies in ...... mall cell lung cancer (Review)

@nl

type

label

Pemetrexed clinical studies in ...... mall cell lung cancer (Review)

@ast

Pemetrexed clinical studies in ...... mall cell lung cancer (Review)

@en

Pemetrexed clinical studies in ...... mall cell lung cancer (Review)

@nl

prefLabel

Pemetrexed clinical studies in ...... mall cell lung cancer (Review)

@ast

Pemetrexed clinical studies in ...... mall cell lung cancer (Review)

@en

Pemetrexed clinical studies in ...... mall cell lung cancer (Review)

@nl

P1433

Q28081243-776FBB8A-D008-4D58-82DC-A6F9E4B1BC02

P1476

Q28081243-B736890D-B1C5-4D73-87ED-F8CD63FACB13

P2093

Q28081243-B362D23F-D2AC-4F66-88C4-7A6EBCD8AC77

Q28081243-C1373F47-610F-4968-A564-0EC4DAA6E5CB

Q28081243-E4F0E7F0-3DA6-4B49-8218-54ECE5872E2C

Q28081243-F557FEB5-7782-4F85-8BE7-73E21F64E39A

P275

Q28081243-208F87D3-842B-48F2-882C-B0A0CBC55F97

P2860

Q28081243-05EC44CE-CAF4-4E1C-9584-2EA4A302EA00

Q28081243-0EAC6AF8-5EED-4419-AF02-0B4E13333845

Q28081243-0EAEA084-9A8C-40DA-8435-C2F0905F50AC

Q28081243-129DE93C-F297-44E3-B008-6C47C0FBFD31

Q28081243-15E46E88-647D-461F-BD35-085BAC36AF57

Q28081243-2271E447-CF11-4B2C-AA05-029585AF88E7

Q28081243-30C3059B-A380-4C59-B328-DBD5B4DD2A03

Q28081243-30F79BDC-648F-4BA7-846F-04B2C5566A19

Q28081243-351F8108-EA79-4B2E-A4DD-490647E769BB

Q28081243-3D4CF3AC-B1B3-47FB-A6E0-7AC795AD8C84

P304

Q28081243-32990316-0425-4065-8BD2-4F85BA24D1B8

P31

Q28081243-A03F9871-85A6-42A5-9C2C-1BFE316B4E45

Q28081243-B4B326DA-C874-4BEE-BBC3-385B5C8F6FA7

P356

Q28081243-0B4170C7-76BB-4246-AEC7-246519763D8C

P407

Q28081243-CDF7F0FD-84C1-4272-A24F-8D7E8630E502

P433

Q28081243-BB2E3E62-2927-4CD8-A8F5-C9A06E96E01A

P478

Q28081243-6A4F2364-A166-4345-A30A-D76C91301A54

P5008

Q28081243-4CC50984-7991-4760-8FC8-52645978C86B

P577

Q28081243-17957C10-9FE1-4309-B647-05D8B45E8FF9

Q28081243-1E0BEA81-25E5-437A-930D-9A9F6B8EE183

P5875

Q28081243-A8782AD5-0DE3-4B31-90B1-9EB9085CE07B

P698

Q28081243-85560947-0520-41F4-A597-7E274D7057A0

P921

Q28081243-04B1C55C-3823-43F0-A793-E6561FB6E822

Q28081243-632A6A64-0E70-4876-BA16-571C343EB9CC

Q28081243-6E41537E-8A37-4F42-8212-9DBF6E886803

Q28081243-909A7254-126D-4DC8-9A1B-123611881978

P932

Q28081243-5CFDE287-EC2F-4E77-B491-E9C60BF88DBD

P356

P1433

International Journal of Oncology

P1476

Pemetrexed clinical studies in ...... mall cell lung cancer (Review)

@en

P2093

Carla Grul

http://www.w3.org/2001/XMLSchema#string

Coleman Obasaju

http://www.w3.org/2001/XMLSchema#string

David Spigel

http://www.w3.org/2001/XMLSchema#string

Ralph Zinner

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivatives

P2860

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.

Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.

Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

P304

13-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/IJO.2015.3219

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283330026

http://www.w3.org/2001/XMLSchema#string

P698

26530033

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

non-small-cell lung carcinoma

biomedical investigative technique

P932

4734604

http://www.w3.org/2001/XMLSchema#string